[{"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-001", "question": "A 45-year-old man with a history of migraine presents with acute onset of right-sided hemiparesis and aphasia. MRI shows restricted diffusion in the left middle cerebral artery territory, but no large vessel occlusion on angiography. Lumbar puncture reveals normal opening pressure, 5 WBCs/μL (all lymphocytes), protein 45 mg/dL, glucose 60 mg/dL, and negative oligoclonal bands. Serum testing is positive for anti-NMDA receptor antibodies. What is the most appropriate next step in management?", "options": ["Initiate intravenous thrombolysis", "Administer high-dose intravenous methylprednisolone", "Start rituximab infusion", "Perform plasmapheresis", "Administer acyclovir empirically"], "answer": "C", "answer_index": 2, "explanation": "The presentation suggests anti-NMDA receptor encephalitis mimicking stroke, and rituximab is indicated for refractory cases or as first-line in severe presentations per subspecialty guidelines. High-dose steroids are often initial, but in antibody-positive cases with stroke-like features, rituximab targets B-cell depletion more effectively. Plasmapheresis is an alternative but not superior in this context without evidence of fulminant progression.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: M (primary; secondary U). Verdict on keyed answer: Miskeyed and Not uniquely determinable. Key stem clues: Acute right hemiparesis and aphasia in a 45-year-old with migraine history; MRI restricted diffusion in left MCA without large vessel occlusion; LP with mild lymphocytic pleocytosis, normal protein/glucose, negative oligoclonal bands; positive serum anti-NMDA receptor antibodies—pointing to anti-NMDA receptor encephalitis as stroke mimic, but lacking severity indicators (e.g., refractory status, rapid progression) or discriminators between first-line therapies. Main logical issue(s): Multiple answers defensible (B and D) as both are standard first-line immunotherapies (steroids or plasmapheresis) per guidelines; stem underspecified tos no details to choose uniquely, leading to ambiguity in 'most appropriate next step' without clues favoring one over the other. Main medical accuracy issue(s): Keyed answer C (rituximab) and rationale inaccurately position it as first-line for severe presentations, contradicting mainstream standards (e.g., first-line is steroids/IVIG/PLEX, rituximab for refractory cases); serum-only antibodies without CSF confirmation is atypical for definitive diagnosis but item assumes it. Minimal fix: Revise key to B (methylprednisolone), update rationale to align with guidelines, and add stem detail like 'severe respiratory compromise' to justify escalating beyond initial steroids if needed.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (primary; secondary U). Verdict on keyed answer: Miskeyed and Not uniquely determinable. Key stem clues: Acute right hemiparesis and aphasia in a 45-year-old with migraine history; MRI restricted diffusion in left MCA without large vessel occlusion; LP with mild lymphocytic pleocytosis, normal protein/glucose, negative oligoclonal bands; positive serum anti-NMDA receptor antibodies—pointing to anti-NMDA receptor encephalitis as stroke mimic, but lacking severity indicators (e.g., refractory status, rapid progression) or discriminators between first-line therapies. Main logical issue(s): Multiple answers defensible (B and D) as both are standard first-line immunotherapies (steroids or plasmapheresis) per guidelines; stem underspecified tos no details to choose uniquely, leading to ambiguity in 'most appropriate next step' without clues favoring one over the other. Main medical accuracy issue(s): Keyed answer C (rituximab) and rationale inaccurately position it as first-line for severe presentations, contradicting mainstream standards (e.g., first-line is steroids/IVIG/PLEX, rituximab for refractory cases); serum-only antibodies without CSF confirmation is atypical for definitive diagnosis but item assumes it. Minimal fix: Revise key to B (methylprednisolone), update rationale to align with guidelines, and add stem detail like 'severe respiratory compromise' to justify escalating beyond initial steroids if needed.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-002", "question": "A 62-year-old woman with Parkinson's disease on levodopa/carbidopa develops sudden visual hallucinations and paranoia. She has no fever, normal vital signs, and her Unified Parkinson's Disease Rating Scale score has worsened by 15 points. CSF analysis shows 10 WBCs/μL (mononuclear), protein 55 mg/dL, and negative PCR for herpes simplex virus. What is the most likely underlying mechanism?", "options": ["Dopaminergic overstimulation in mesolimbic pathways", "Alpha-synuclein aggregation in occipital lobes", "Autoimmune encephalitis with anti-LGI1 antibodies", "Lewy body deposition in limbic structures", "Serotonergic imbalance from medication withdrawal"], "answer": "C", "answer_index": 2, "explanation": "This scenario points to anti-LGI1 encephalitis, which can mimic psychiatric decompensation in Parkinson's patients and is associated with faciobrachial dystonic seizures or hallucinations. Dopaminergic effects are common but do not explain the CSF pleocytosis. Lewy body involvement is typical in dementia with Lewy bodies but lacks the acute inflammatory CSF findings here.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: sudden visual hallucinations and paranoia in a Parkinson's patient on levodopa/carbidopa, with UPDRS worsening by 15 points, mild CSF mononuclear pleocytosis (10 WBCs/μL), elevated protein (55 mg/dL), negative HSV PCR, no fever, and normal vitals. These findings, particularly the inflammatory CSF changes, point to an acute process beyond typical PD progression or medication effects, supporting autoimmune encephalitis as the mechanism. Main logical issue(s), if any: None; the stem provides sufficient discriminators (CSF inflammation rules out non-inflammatory options like A, B, D, E), allowing C as the unique best. Main medical accuracy issue(s), if any: Mostly accurate per current guidelines; anti-LGI1 encephalitis can present with psychiatric symptoms and mild CSF changes in PD patients, mimicking decompensation, though typical features like hyponatremia or faciobrachial dystonic seizures are absent, representing minor nuance omission but not inaccuracy. Minimal fix: Add 'hyponatremia (Na 128 mEq/L)' to the vignette to strengthen specificity for anti-LGI1 without altering core logic.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: sudden visual hallucinations and paranoia in a Parkinson's patient on levodopa/carbidopa, with UPDRS worsening by 15 points, mild CSF mononuclear pleocytosis (10 WBCs/μL), elevated protein (55 mg/dL), negative HSV PCR, no fever, and normal vitals. These findings, particularly the inflammatory CSF changes, point to an acute process beyond typical PD progression or medication effects, supporting autoimmune encephalitis as the mechanism. Main logical issue(s), if any: None; the stem provides sufficient discriminators (CSF inflammation rules out non-inflammatory options like A, B, D, E), allowing C as the unique best. Main medical accuracy issue(s), if any: Mostly accurate per current guidelines; anti-LGI1 encephalitis can present with psychiatric symptoms and mild CSF changes in PD patients, mimicking decompensation, though typical features like hyponatremia or faciobrachial dystonic seizures are absent, representing minor nuance omission but not inaccuracy. Minimal fix: Add 'hyponatremia (Na 128 mEq/L)' to the vignette to strengthen specificity for anti-LGI1 without altering core logic.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-003", "question": "A 28-year-old woman at 32 weeks gestation presents with severe pelvic pain and vaginal bleeding. Ultrasound shows a low-lying placenta with abnormal lacunae and loss of the retroplacental clear space. MRI confirms myometrial thinning and turbulent flow voids. What is the most appropriate management strategy?", "options": ["Expectant management with bed rest", "Immediate cesarean delivery", "Uterine artery embolization", "Balloon tamponade post-delivery", "Prophylactic internal iliac artery ligation"], "answer": "E", "answer_index": 4, "explanation": "This describes placenta accreta spectrum, and prophylactic internal iliac artery ligation reduces hemorrhage risk during planned cesarean hysterectomy in high-risk cases. Immediate delivery risks uncontrolled bleeding without preparation. Embolization is adjunctive but not primary in antenatal planning for accreta.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: M (secondary U). Verdict on keyed answer: Miskeyed / Not uniquely determinable. Key stem clues: 32 weeks gestation, severe pelvic pain, vaginal bleeding, ultrasound showing low-lying placenta with abnormal lacunae and loss of retroplacental clear space, MRI with myometrial thinning and turbulent flow voids—these suggest placenta accreta spectrum (PAS) but do not specify hemodynamic stability, bleeding severity, or fetal status, failing to drive a unique best answer. Main logical issue(s): Multiple answers defensible (M) due to underspecification (U); depending on unstated assumptions, B (immediate cesarean) could be best if unstable with heavy bleeding, A (expectant) if stable and minor symptoms, or preparation involving E if planned delivery feasible—stem's 'severe' symptoms create ambiguity without clear discrimination. Main medical accuracy issue(s): Keyed E (prophylactic internal iliac artery ligation) is an adjunctive technique sometimes used in PAS to reduce bleeding during planned cesarean hysterectomy, but it is not the primary or most appropriate management strategy per ACOG/SMFM guidelines, which emphasize multidisciplinary planned delivery at 34-36 weeks for stable cases; presenting it as such is misleading and outdated, as evidence for routine ligation is limited. Minimal fix: Add to stem 'The patient is hemodynamically stable with minimal bleeding' and change key to B, or introduce a new option like 'Multidisciplinary planned cesarean hysterectomy at 34 weeks' as key.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (secondary U). Verdict on keyed answer: Miskeyed / Not uniquely determinable. Key stem clues: 32 weeks gestation, severe pelvic pain, vaginal bleeding, ultrasound showing low-lying placenta with abnormal lacunae and loss of retroplacental clear space, MRI with myometrial thinning and turbulent flow voids—these suggest placenta accreta spectrum (PAS) but do not specify hemodynamic stability, bleeding severity, or fetal status, failing to drive a unique best answer. Main logical issue(s): Multiple answers defensible (M) due to underspecification (U); depending on unstated assumptions, B (immediate cesarean) could be best if unstable with heavy bleeding, A (expectant) if stable and minor symptoms, or preparation involving E if planned delivery feasible—stem's 'severe' symptoms create ambiguity without clear discrimination. Main medical accuracy issue(s): Keyed E (prophylactic internal iliac artery ligation) is an adjunctive technique sometimes used in PAS to reduce bleeding during planned cesarean hysterectomy, but it is not the primary or most appropriate management strategy per ACOG/SMFM guidelines, which emphasize multidisciplinary planned delivery at 34-36 weeks for stable cases; presenting it as such is misleading and outdated, as evidence for routine ligation is limited. Minimal fix: Add to stem 'The patient is hemodynamically stable with minimal bleeding' and change key to B, or introduce a new option like 'Multidisciplinary planned cesarean hysterectomy at 34 weeks' as key.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-004", "question": "A 35-year-old woman with endometriosis undergoes laparoscopic excision and develops postoperative fever, leukocytosis, and pelvic pain. CT shows a 5 cm complex adnexal mass with gas bubbles. Blood cultures are negative, but vaginal cultures grow mixed anaerobes. What is the most likely diagnosis?", "options": ["Ovarian abscess from bowel perforation", "Endometrioma superinfection", "Tubo-ovarian abscess from pelvic inflammatory disease", "Postoperative hematoma with secondary infection", "Clostridial myonecrosis of the uterus"], "answer": "A", "answer_index": 0, "explanation": "Bowel perforation during endometriosis surgery can lead to ovarian abscess with gas-forming anaerobes, explaining the imaging and cultures. Endometrioma infection is less likely without prior instrumentation. Tubo-ovarian abscess typically involves gonadal pathogens, not mixed anaerobes from bowel flora.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include postoperative fever, leukocytosis, pelvic pain after laparoscopic endometriosis excision, CT showing 5 cm complex adnexal mass with gas bubbles, negative blood cultures, and vaginal cultures growing mixed anaerobes. These suggest an anaerobic infection likely from bowel flora, with gas formation pointing to perforation during surgery, making A (ovarian abscess from bowel perforation) the most defensible. No main logical issues; the stem provides sufficient discriminating details (surgical context, imaging with gas, bowel-like anaerobes) to identify A as uniquely best without contradictions or underspecification. Alternatives are inferior: B lacks typical instrumentation for superinfection and bowel flora mismatch; C involves gonadal pathogens, not mixed anaerobes; D doesn't explain gas bubbles or anaerobic source; E targets uterus, not adnexa, and is less likely post-laparoscopy. No main medical accuracy issues; aligns with standard knowledge of endometriosis surgery risks (bowel perforation leading to polymicrobial abscess), current guidelines on postoperative infections, and imaging findings. Minimal fix: None needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include postoperative fever, leukocytosis, pelvic pain after laparoscopic endometriosis excision, CT showing 5 cm complex adnexal mass with gas bubbles, negative blood cultures, and vaginal cultures growing mixed anaerobes. These suggest an anaerobic infection likely from bowel flora, with gas formation pointing to perforation during surgery, making A (ovarian abscess from bowel perforation) the most defensible. No main logical issues; the stem provides sufficient discriminating details (surgical context, imaging with gas, bowel-like anaerobes) to identify A as uniquely best without contradictions or underspecification. Alternatives are inferior: B lacks typical instrumentation for superinfection and bowel flora mismatch; C involves gonadal pathogens, not mixed anaerobes; D doesn't explain gas bubbles or anaerobic source; E targets uterus, not adnexa, and is less likely post-laparoscopy. No main medical accuracy issues; aligns with standard knowledge of endometriosis surgery risks (bowel perforation leading to polymicrobial abscess), current guidelines on postoperative infections, and imaging findings. Minimal fix: None needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-005", "question": "A 58-year-old man with hypertrophic cardiomyopathy presents with syncope. Echocardiogram shows left ventricular outflow tract gradient of 80 mmHg at rest, increasing to 120 mmHg with Valsalva. He is on beta-blockers but remains symptomatic. Genetic testing reveals a MYH7 mutation. What is the most appropriate next intervention?", "options": ["Alcohol septal ablation", "Surgical myectomy", "Implantable cardioverter-defibrillator placement", "Dual-chamber pacing", "Mavacamten therapy"], "answer": "E", "answer_index": 4, "explanation": "Mavacamten, a cardiac myosin inhibitor, is indicated for symptomatic obstructive hypertrophic cardiomyopathy refractory to beta-blockers, targeting the underlying MYH7-related hypercontractility. Alcohol ablation and myectomy are invasive options for severe cases, but mavacamten offers medical management first. ICD is for arrhythmia risk, not outflow obstruction.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: 58-year-old with hypertrophic cardiomyopathy (HCM), syncope, LVOT gradient 80 mmHg at rest increasing to 120 mmHg with Valsalva, symptomatic despite beta-blockers, MYH7 mutation. These indicate symptomatic obstructive HCM refractory to first-line therapy, with genetic confirmation of myosin-related pathology.\\nMain logical issue(s), if any: None; the stem provides sufficient details to discriminate options without contradictions or underspecification, supporting E as uniquely best.\\nMain medical accuracy issue(s), if any: None; aligns with 2020 AHA/ACC HCM guidelines and FDA approval of mavacamten (2022) for symptomatic obstructive HCM after beta-blocker failure, targeting MYH7 hypercontractility. Alternatives: A/B are invasive for refractory cases but not first next after beta-blockers per guidelines; C addresses arrhythmia risk, not obstruction; D is outdated for obstruction management.\\nMinimal fix: None required; item is already unambiguous and accurate.\\n\\nBest-answer defensibility:\\na) Question asks for next intervention in symptomatic obstructive HCM refractory to beta-blockers.\\nb) Key findings: syncope, high LVOT gradients (rest/provoked), MYH7 mutation, beta-blocker failure.\\nc) Most likely: Advance to cardiac myosin inhibitor for medical management of obstruction.\\nd) Keyed E (Mavacamten) fits: Guideline-recommended, non-invasive, targets myosin mutation; assumes no contraindications (unstated but not required).\\ne) A: Invasive, for severe refractory cases; B: Surgical, similar to A; C: For SCD risk, not specified; D: Less effective per evidence.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: 58-year-old with hypertrophic cardiomyopathy (HCM), syncope, LVOT gradient 80 mmHg at rest increasing to 120 mmHg with Valsalva, symptomatic despite beta-blockers, MYH7 mutation. These indicate symptomatic obstructive HCM refractory to first-line therapy, with genetic confirmation of myosin-related pathology.\nMain logical issue(s), if any: None; the stem provides sufficient details to discriminate options without contradictions or underspecification, supporting E as uniquely best.\nMain medical accuracy issue(s), if any: None; aligns with 2020 AHA/ACC HCM guidelines and FDA approval of mavacamten (2022) for symptomatic obstructive HCM after beta-blocker failure, targeting MYH7 hypercontractility. Alternatives: A/B are invasive for refractory cases but not first next after beta-blockers per guidelines; C addresses arrhythmia risk, not obstruction; D is outdated for obstruction management.\nMinimal fix: None required; item is already unambiguous and accurate.\n\nBest-answer defensibility:\na) Question asks for next intervention in symptomatic obstructive HCM refractory to beta-blockers.\nb) Key findings: syncope, high LVOT gradients (rest/provoked), MYH7 mutation, beta-blocker failure.\nc) Most likely: Advance to cardiac myosin inhibitor for medical management of obstruction.\nd) Keyed E (Mavacamten) fits: Guideline-recommended, non-invasive, targets myosin mutation; assumes no contraindications (unstated but not required).\ne) A: Invasive, for severe refractory cases; B: Surgical, similar to A; C: For SCD risk, not specified; D: Less effective per evidence.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-006", "question": "A 70-year-old woman with atrial fibrillation on apixaban develops acute chest pain. Coronary angiography shows spontaneous coronary artery dissection in the left anterior descending artery. She is hemodynamically stable with TIMI 3 flow. What is the most appropriate management?", "options": ["Percutaneous coronary intervention with stenting", "Continuation of apixaban with close monitoring", "Switch to dual antiplatelet therapy", "Surgical bypass grafting", "Conservative management with beta-blockers"], "answer": "E", "answer_index": 4, "explanation": "Conservative management with beta-blockers is preferred for stable spontaneous coronary artery dissection with preserved flow, as it promotes healing and reduces shear stress. Anticoagulation like apixaban increases bleeding risk in dissection. PCI is reserved for unstable cases due to high complication rates.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 70-year-old woman with atrial fibrillation on apixaban presents with acute chest pain; angiography confirms spontaneous coronary artery dissection (SCAD) in the left anterior descending artery; hemodynamically stable with TIMI 3 flow. These indicate a stable SCAD case, where conservative management is preferred to promote healing and reduce shear stress, aligning with guidelines favoring beta-blockers. The keyed answer E fits without requiring unstated assumptions, as it directly addresses the standard approach for stable SCAD. No main logical issues; the stem provides sufficient details to discriminate options without contradictions or underspecification. Alternatives are inferior: A (PCI) is for unstable cases with high complications; B continues apixaban, risking bleeding; C switches to DAPT, unnecessary and bleeding-prone; D (CABG) is excessive for stable dissection. No main medical accuracy issues; consistent with AHA/ESC guidelines on SCAD management, emphasizing conservative therapy with beta-blockers in stable patients, though atrial fibrillation necessitates careful anticoagulation balancing, which is implicitly handled in conservative approach. Minimal fix: None needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 70-year-old woman with atrial fibrillation on apixaban presents with acute chest pain; angiography confirms spontaneous coronary artery dissection (SCAD) in the left anterior descending artery; hemodynamically stable with TIMI 3 flow. These indicate a stable SCAD case, where conservative management is preferred to promote healing and reduce shear stress, aligning with guidelines favoring beta-blockers. The keyed answer E fits without requiring unstated assumptions, as it directly addresses the standard approach for stable SCAD. No main logical issues; the stem provides sufficient details to discriminate options without contradictions or underspecification. Alternatives are inferior: A (PCI) is for unstable cases with high complications; B continues apixaban, risking bleeding; C switches to DAPT, unnecessary and bleeding-prone; D (CABG) is excessive for stable dissection. No main medical accuracy issues; consistent with AHA/ESC guidelines on SCAD management, emphasizing conservative therapy with beta-blockers in stable patients, though atrial fibrillation necessitates careful anticoagulation balancing, which is implicitly handled in conservative approach. Minimal fix: None needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-007", "question": "A 40-year-old man returning from West Africa presents with fever, myalgias, and petechial rash. Labs show thrombocytopenia, elevated liver enzymes, and PCR positive for Lassa virus. He develops acute kidney injury with oliguria. What is the most appropriate therapeutic intervention?", "options": ["Intravenous ribavirin", "Supportive care with hemodialysis", "Convalescent plasma transfusion", "Favipiravir administration", "Monoclonal antibody therapy"], "answer": "A", "answer_index": 0, "explanation": "Intravenous ribavirin is the mainstay for Lassa fever, reducing mortality especially when initiated early, and it addresses viremia in cases with renal involvement. Supportive care is essential but not sufficient alone. Favipiravir is investigational and not standard for Lassa.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include travel from West Africa, fever, myalgias, petechial rash, thrombocytopenia, elevated liver enzymes, PCR-confirmed Lassa virus, and acute kidney injury with oliguria—these hallmark Lassa fever, where early antiviral therapy is critical. The question asks for the most appropriate therapeutic intervention, implying the primary targeted treatment. Intravenous ribavirin (A) fits as the mainstay per WHO/CDC guidelines, reducing mortality by addressing viremia, even with renal involvement (dose adjustment may be needed but not specified as a barrier). Alternatives: B (supportive care with hemodialysis) is essential for AKI but insufficient alone without antiviral; C (convalescent plasma) lacks evidence for Lassa; D (favipiravir) is investigational, not standard; E (monoclonal antibody) is not established for Lassa. Main logical issue(s): None; stem provides sufficient details for discrimination without contradictions or underspecification. Main medical accuracy issue(s): None; aligns with current standards—ribavirin is recommended for severe Lassa, supportive care adjunctive. Item is clinically realistic and board-relevant. Minimal fix: None required; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include travel from West Africa, fever, myalgias, petechial rash, thrombocytopenia, elevated liver enzymes, PCR-confirmed Lassa virus, and acute kidney injury with oliguria—these hallmark Lassa fever, where early antiviral therapy is critical. The question asks for the most appropriate therapeutic intervention, implying the primary targeted treatment. Intravenous ribavirin (A) fits as the mainstay per WHO/CDC guidelines, reducing mortality by addressing viremia, even with renal involvement (dose adjustment may be needed but not specified as a barrier). Alternatives: B (supportive care with hemodialysis) is essential for AKI but insufficient alone without antiviral; C (convalescent plasma) lacks evidence for Lassa; D (favipiravir) is investigational, not standard; E (monoclonal antibody) is not established for Lassa. Main logical issue(s): None; stem provides sufficient details for discrimination without contradictions or underspecification. Main medical accuracy issue(s): None; aligns with current standards—ribavirin is recommended for severe Lassa, supportive care adjunctive. Item is clinically realistic and board-relevant. Minimal fix: None required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-008", "question": "A 55-year-old immunocompromised patient with lung transplant develops dyspnea and ground-glass opacities on CT. Bronchoalveolar lavage PCR is positive for Pneumocystis jirovecii, but serum beta-D-glucan is negative. He is on trimethoprim-sulfamethoxazole prophylaxis. What explains the breakthrough infection?", "options": ["Dihydropteroate synthase gene mutation", "Non-adherence to prophylaxis", "Concurrent cytomegalovirus co-infection", "Inadequate dosing in obesity", "Atovaquone cross-resistance"], "answer": "A", "answer_index": 0, "explanation": "Mutations in the dihydropteroate synthase gene confer resistance to sulfamethoxazole in Pneumocystis, leading to breakthrough despite prophylaxis in immunocompromised hosts. Non-adherence is common but less likely with negative beta-D-glucan suggesting low burden. CMV co-infection exacerbates but does not cause resistance.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Immunocompromised lung transplant patient on TMP-SMX prophylaxis with breakthrough P. jirovecii PCR-positive infection, dyspnea, ground-glass opacities, but notably negative serum beta-D-glucan, which suggests low fungal burden atypical for non-adherence-related full-blown infection. This discriminates toward resistance mechanism over common alternatives like non-adherence. Main logical issue(s), if any: None; the stem provides sufficient clues (negative beta-D-glucan implying adherence with low-burden breakthrough) to support A as uniquely defensible, with alternatives eliminable (B not fitting low burden; C exacerbates but doesn't cause breakthrough; D lacks obesity mention; E irrelevant as not on atovaquone). Main medical accuracy issue(s), if any: Minor nuance—beta-D-glucan negativity in confirmed PJP is uncommon (sensitivity >90%) but can occur in low-burden or early cases; rationale's use to discount non-adherence is reasonable but assumes correlation with burden, which is generally accepted though not absolute. Overall aligns with guidelines on DHPS mutations causing sulfa resistance in PJP prophylaxis failure in immunocompromised hosts. Minimal fix: Add 'confirmed adherence' to stem to further eliminate B ambiguity, enhancing clarity without altering intent.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Immunocompromised lung transplant patient on TMP-SMX prophylaxis with breakthrough P. jirovecii PCR-positive infection, dyspnea, ground-glass opacities, but notably negative serum beta-D-glucan, which suggests low fungal burden atypical for non-adherence-related full-blown infection. This discriminates toward resistance mechanism over common alternatives like non-adherence. Main logical issue(s), if any: None; the stem provides sufficient clues (negative beta-D-glucan implying adherence with low-burden breakthrough) to support A as uniquely defensible, with alternatives eliminable (B not fitting low burden; C exacerbates but doesn't cause breakthrough; D lacks obesity mention; E irrelevant as not on atovaquone). Main medical accuracy issue(s), if any: Minor nuance—beta-D-glucan negativity in confirmed PJP is uncommon (sensitivity >90%) but can occur in low-burden or early cases; rationale's use to discount non-adherence is reasonable but assumes correlation with burden, which is generally accepted though not absolute. Overall aligns with guidelines on DHPS mutations causing sulfa resistance in PJP prophylaxis failure in immunocompromised hosts. Minimal fix: Add 'confirmed adherence' to stem to further eliminate B ambiguity, enhancing clarity without altering intent.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-009", "question": "A 50-year-old woman with rheumatoid arthritis on tofacitinib presents with symmetric polyarthritis flare, fever, and macular rash. Labs show pancytopenia, ferritin 10,000 ng/mL, triglycerides 400 mg/dL, and fibrinogen 100 mg/dL. Bone marrow biopsy reveals hemophagocytosis. What is the most appropriate initial treatment?", "options": ["High-dose glucocorticoids", "Cyclosporine A", "Anakinra", "Etoposide-based chemotherapy", "Intravenous immunoglobulin"], "answer": "C", "answer_index": 2, "explanation": "Anakinra, an IL-1 inhibitor, is effective for macrophage activation syndrome in rheumatoid arthritis, targeting cytokine storm and improving survival without broad immunosuppression. Glucocorticoids are adjunctive but insufficient alone in JAK inhibitor-associated cases. Etoposide is for refractory HLH but not first-line here.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues include RA on tofacitinib, polyarthritis flare, fever, macular rash, pancytopenia, ferritin 10,000 ng/mL, triglycerides 400 mg/dL, fibrinogen 100 mg/dL, and bone marrow hemophagocytosis, collectively diagnostic for macrophage activation syndrome (MAS), a secondary hemophagocytic lymphohistiocytosis (HLH) variant in rheumatic disease. These findings drive a unique best answer by implicating a cytokine-driven process responsive to targeted IL-1 inhibition, especially in JAK inhibitor-associated cases. No main logical issues; the vignette is internally consistent, supports discrimination among options, and identifies anakinra as the single best initial therapy without requiring unstated assumptions. No main medical accuracy issues; anakinra aligns with current guidelines for MAS in adult rheumatic diseases (e.g., EULAR recommendations), targeting IL-1 in cytokine storm, with glucocorticoids as adjunctive rather than primary, and etoposide reserved for refractory HLH. Item reflects board-relevant knowledge on MAS management, avoiding broad immunosuppression. Minimal fix: None needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues include RA on tofacitinib, polyarthritis flare, fever, macular rash, pancytopenia, ferritin 10,000 ng/mL, triglycerides 400 mg/dL, fibrinogen 100 mg/dL, and bone marrow hemophagocytosis, collectively diagnostic for macrophage activation syndrome (MAS), a secondary hemophagocytic lymphohistiocytosis (HLH) variant in rheumatic disease. These findings drive a unique best answer by implicating a cytokine-driven process responsive to targeted IL-1 inhibition, especially in JAK inhibitor-associated cases. No main logical issues; the vignette is internally consistent, supports discrimination among options, and identifies anakinra as the single best initial therapy without requiring unstated assumptions. No main medical accuracy issues; anakinra aligns with current guidelines for MAS in adult rheumatic diseases (e.g., EULAR recommendations), targeting IL-1 in cytokine storm, with glucocorticoids as adjunctive rather than primary, and etoposide reserved for refractory HLH. Item reflects board-relevant knowledge on MAS management, avoiding broad immunosuppression. Minimal fix: None needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed124", "question_id": "20251201T041413890Z_grok-4-0709_seed124-010", "question": "A 65-year-old man with giant cell arteritis on prednisone taper develops jaw claudication and vision loss. ESR is 80 mm/hr, and temporal artery biopsy is negative. CTA shows aortic arch involvement. What is the most appropriate escalation in therapy?", "options": ["Increase prednisone to 60 mg daily", "Add methotrexate", "Initiate tocilizumab", "Start cyclophosphamide", "Perform temporal artery ultrasound"], "answer": "C", "answer_index": 2, "explanation": "Tocilizumab, an IL-6 inhibitor, is indicated for refractory giant cell arteritis with large vessel involvement, reducing relapse and steroid requirements. High-dose prednisone is initial but inadequate for escalation in biopsy-negative cases. Methotrexate is steroid-sparing but less effective for vision-threatening disease.", "generator_model": "grok-4-0709", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 65-year-old with GCA on prednisone taper relapsing with jaw claudication, vision loss, elevated ESR (80 mm/hr), negative temporal artery biopsy, but CTA-confirmed aortic arch involvement, driving need for therapy escalation in refractory large-vessel GCA. These findings imply steroid-refractory disease with vision-threatening features, uniquely supporting tocilizumab as the best escalation per guidelines. Main logical issues: None; stem provides sufficient details for discrimination without contradictions or underspecification, allowing single best answer (C) over alternatives. Evaluation: (a) Question asks for optimal escalation in relapsing vision-threatening GCA with large-vessel involvement. (b) Discriminating findings: relapse on taper (positive: new symptoms, high ESR, CTA positivity; negative: biopsy-negative but not ruling out large-vessel disease). (c) Implied: Refractory large-vessel GCA needing biologic. (d) Keyed C fits as IL-6 inhibitor reducing relapses/steroid needs; assumes guideline adherence. (e) A worse: mere steroid increase inadequate for refractory case; B: methotrexate less effective for urgent vision threat; D: cyclophosphamide reserved for severe vasculitis, not standard GCA; E: ultrasound diagnostic, not therapeutic escalation. Medical accuracy: Consistent with ACR/EULAR guidelines endorsing tocilizumab for refractory GCA; no inaccuracies or outdated elements. Minimal fix: None required; item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: 65-year-old with GCA on prednisone taper relapsing with jaw claudication, vision loss, elevated ESR (80 mm/hr), negative temporal artery biopsy, but CTA-confirmed aortic arch involvement, driving need for therapy escalation in refractory large-vessel GCA. These findings imply steroid-refractory disease with vision-threatening features, uniquely supporting tocilizumab as the best escalation per guidelines. Main logical issues: None; stem provides sufficient details for discrimination without contradictions or underspecification, allowing single best answer (C) over alternatives. Evaluation: (a) Question asks for optimal escalation in relapsing vision-threatening GCA with large-vessel involvement. (b) Discriminating findings: relapse on taper (positive: new symptoms, high ESR, CTA positivity; negative: biopsy-negative but not ruling out large-vessel disease). (c) Implied: Refractory large-vessel GCA needing biologic. (d) Keyed C fits as IL-6 inhibitor reducing relapses/steroid needs; assumes guideline adherence. (e) A worse: mere steroid increase inadequate for refractory case; B: methotrexate less effective for urgent vision threat; D: cyclophosphamide reserved for severe vasculitis, not standard GCA; E: ultrasound diagnostic, not therapeutic escalation. Medical accuracy: Consistent with ACR/EULAR guidelines endorsing tocilizumab for refractory GCA; no inaccuracies or outdated elements. Minimal fix: None required; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]